Genmab’s petosemtamab in combination with Keytruda showed a positive early analysis in a late-stage trial for first-line head and neck squamous cell carcinoma that is PD-L1 positive, cutting the risk of death by half versus Keytruda alone. The results sent Genmab shares to record highs as the company adds yet another late-stage readout in recent weeks. The regimen met dual main objectives on response rates and survival in people receiving no more than one prior line of therapy for advanced disease. Genmab has said it will share detailed results with regulators and present at a future medical meeting, while market attention also turns to how the data could help petosemtamab replace revenues in the post–Darzalex exclusivity window. The stock reaction also reflects the company’s broader pipeline momentum, following earlier late-stage successes in lymphoma and ovarian cancer reported through separate programs.